Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q4 2025 earnings summary

20 Mar, 2026

Executive summary

  • Retail gross revenue reached R$1.68 billion in 4Q25, up 18.2% year-over-year, and R$5.91 billion in 2025, up 17.0% from 2024.

  • Adjusted net income grew 35.0% in 4Q25 and 15.3% in 2025, with margins of 2.7% and 2.3%, respectively.

  • Adjusted EBITDA rose 27.9% in 4Q25 and 21.4% in 2025, with margins expanding to 6.2% and 5.4%.

  • 2025 marked the end of a five-year growth cycle, doubling revenue since 2020 and expanding store count and margins, with a focus on omnichannel and digital transformation.

  • Strategic exit from wholesale operations in 2024 sharpened focus on retail and operational efficiency.

Financial highlights

  • Retail gross revenue CAGR (2020–2025) was 17.0%, with consistent quarterly and annual growth.

  • Adjusted EBITDA CAGR (2020–2025) was 20.0%, outpacing revenue growth.

  • Adjusted net income CAGR (2020–2025) was 14.1%.

  • Gross revenue reached R$5.94 billion in 2025, up 11.5% year-over-year; retail gross revenue was R$5.91 billion, up 17.0%.

  • Free cash flow for the year was R$106.3 million, with positive generation in all quarters.

Outlook and guidance

  • Strategic focus on digitalization, private label expansion, and logistics to sustain growth.

  • Roadmap targets by 2030: R$11.5–12 billion in revenue, 6.7–7% EBITDA margin, and 950–1,000 stores.

  • Growth to be driven by higher sales per store, regional expansion, digitalization, and new service offerings.

  • Continued expansion in South and Southeast regions, with investments in store network and logistics.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more